510(k) K253240

PrecivityAD2 Test by C2N Diagnostics, LLC — Product Code SET

K253240 is an FDA 510(k) premarket notification submitted by C2N Diagnostics, LLC for the device "PrecivityAD2 Test". The FDA issued a decision of Substantially Equivalent on Aug 19, 2026. The device falls under product code SET (Immunoassay Blood Test For Amyloid Pathology Assessment), a Class II device regulated under 21 CFR 866.5840.

Clearance details

Decision
SESE (Substantially Equivalent)
Decision Date
Aug 19, 2026
Date Received
Sep 29, 2025
Clearance Type
Traditional
Expedited Review
No
Third Party Review
No

Device classification

Device Name
Immunoassay Blood Test For Amyloid Pathology Assessment
Device Class
Class II
Regulation Number
866.5840
Review Panel
IM
Submission Type
510(k)

An Immunoassay blood test for amyloid pathology assessment is an in vitro diagnostic test used to identify patients with amyloid pathology associated with Alzheimer’s Disease who have signs and symptoms of cognitive decline. The results of the test are to be interpreted in conjunction with other patient clinical information.

Need the full FDA record for C2N Diagnostics, LLC? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: FDA 510(k) database entry for K253240. Report a data issue: hello@regdatalab.com.